Galapagos/€GLPG
07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX
About Galapagos
Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.
Ticker
€GLPG
Sector
Primary listing
AEX
Industry
Biotechnology
Headquarters
Employees
704
ISIN
BE0003818359
Website
Galapagos Metrics
BasicAdvanced
€1.6B
-
-€2.57
-0.06
-
Price and volume
Market cap
€1.6B
Beta
-0.06
52-week high
€31.08
52-week low
€20.00
Average daily volume
114K
Financial strength
Current ratio
7.945
Quick ratio
7.736
Long term debt to equity
0.283
Total debt to equity
0.395
Interest coverage (TTM)
-217.59%
Profitability
EBITDA (TTM)
-276.282
Gross margin (TTM)
45.46%
Net profit margin (TTM)
-58.83%
Operating margin (TTM)
-108.49%
Effective tax rate (TTM)
1.67%
Revenue per employee (TTM)
€410,000
Management effectiveness
Return on assets (TTM)
-4.66%
Return on equity (TTM)
-6.36%
Valuation
Price to revenue (TTM)
5.492
Price to book
0.57
Price to tangible book (TTM)
0.62
Price to free cash flow (TTM)
-4.988
Free cash flow yield (TTM)
-20.05%
Free cash flow per share (TTM)
-481.53%
Growth
Revenue change (TTM)
18.31%
Earnings per share change (TTM)
-160.73%
3-year revenue growth (CAGR)
-17.18%
10-year revenue growth (CAGR)
12.66%
3-year earnings per share growth (CAGR)
10.36%
10-year earnings per share growth (CAGR)
24.05%
What the Analysts think about Galapagos
Analyst ratings (Buy, Hold, Sell) for Galapagos stock.
Bulls say / Bears say
Galapagos' strategic decision to spin off its innovative medicines unit into a separate publicly traded entity aims to provide clearer business prospects for investors, potentially unlocking shareholder value. (reuters.com)
The spin-off will be well-capitalized with approximately €2.45 billion in cash, providing substantial resources to develop a pipeline of innovative medicines. (reuters.com)
Gilead Sciences Inc., a major partner and shareholder, will maintain a 25% stake in both Galapagos and the new entity, indicating continued confidence and support from a leading industry player. (reuters.com)
Galapagos reported a significant adjusted loss of €2.33 per share for the quarter ended March 31, 2025, missing analyst expectations and indicating financial challenges. (tradingview.com)
Analysts have recently downgraded Galapagos' stock, with a consensus recommendation of 'Reduce' and a 12-month price target of $25.33, reflecting skepticism about the company's near-term prospects. (defenseworld.net)
The planned reorganization is expected to lead to the reduction of around 300 positions in Europe, or around 40% of the group's workforce, which may impact operational efficiency and morale. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Galapagos Financial Performance
Revenues and expenses
Galapagos Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Galapagos stock?
Galapagos (GLPG) has a market cap of €1.6B as of June 30, 2025.
What is the P/E ratio for Galapagos stock?
The price to earnings (P/E) ratio for Galapagos (GLPG) stock is 0 as of June 30, 2025.
Does Galapagos stock pay dividends?
No, Galapagos (GLPG) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Galapagos dividend payment date?
Galapagos (GLPG) stock does not pay dividends to its shareholders.
What is the beta indicator for Galapagos?
Galapagos (GLPG) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.